+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dual Targeted Therapy Market - Global Forecast to 2030- Product Image
Dual Targeted Therapy Market - Global Forecast to 2030- Product Image
Sale

Dual Targeted Therapy Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015556
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dual Targeted Therapy Market grew from USD 361.28 million in 2024 to USD 460.01 million in 2025. It is expected to continue growing at a CAGR of 26.59%, reaching USD 1.48 billion by 2030.

The dual targeted therapy market has emerged as a critical frontier in precision medicine, delivering tailored interventions that simultaneously address multiple molecular pathways. As therapeutic paradigms evolve, the integration of biologic drugs and small molecule therapies has unlocked new avenues for treating complex diseases. Through strategic partnerships, innovative drug development processes and synergistic combination approaches, industry stakeholders are redefining patient outcomes and driving clinical advancement.

In light of accelerating research investments and a surge in regulatory approvals, the landscape demands a comprehensive understanding of market dynamics. This executive summary introduces the foundational concepts of dual targeted therapy, explores key drivers such as technological breakthroughs and patient-centric models, and outlines the strategic imperatives for decision-makers. By framing the current state and emerging trends, it sets the stage for a deeper analysis that equips experts with actionable insights to navigate the rapidly shifting environment.

Transformative Shifts Shaping Dual Targeted Therapy

Over the past decade, transformative shifts have reshaped the dual targeted therapy environment. First, the convergence of high-throughput screening and computational biology has accelerated target identification, empowering developers to design molecules that precisely modulate disease pathways. Additionally, breakthroughs in gene editing and immunotherapy have blurred traditional boundaries, enabling hybrid approaches that harness both biologic and small molecule platforms.

Moreover, regulatory frameworks have adapted to accommodate complex combination regimens, balancing expedited review timelines with rigorous safety standards. Payers have responded by implementing value-based reimbursement models, incentivizing outcomes over unit costs and encouraging real-world evidence generation.

Finally, patient advocacy and digital health solutions have elevated the importance of personalized treatment journeys. Remote monitoring technologies and predictive analytics now integrate seamlessly with clinical protocols, ensuring adaptive dosing and early adverse event detection. These combined shifts underscore a new era in which collaboration among research institutions, biotech innovators and health systems is paramount to sustaining innovation and meeting evolving patient needs.

Cumulative Impact of US Tariffs 2025 on Dual Targeted Therapy

In 2025, the implementation of revised United States tariffs introduced consequential effects on global supply chains for dual targeted therapy components. Increased duties on raw materials, including recombinant proteins and specialty chemicals, have elevated manufacturing costs for both fusion proteins and monoclonal antibodies. Consequently, production budgets have been reallocated to secure alternative suppliers and optimize logistic pathways.

Furthermore, tariffs on advanced formulation technologies and contract development services have prompted companies to explore nearshoring and vertical integration strategies. By establishing regional hubs, organizations mitigate exposure to cross-border levies and enhance supply chain resilience. In parallel, procurement teams have renegotiated vendor contracts to secure long-term pricing stability and preferential terms.

The aggregated impact of these measures has sparked a reevaluation of pricing models, compelling manufacturers to adopt cost-containment innovations such as continuous manufacturing, micro-reactor systems and modular facility designs. Ultimately, this tariff landscape is driving a more agile, decentralized production infrastructure that balances economic efficiency with regulatory compliance.

Key Insights from Market Segmentation Analysis

An in-depth segmentation review reveals that the market’s behavior varies significantly across therapy types, disease indications, patient demographics, mechanism of action, combination strategies and end-user applications. Based on Type Of Therapy, market activity spans Biologic Drugs, which include Fusion Proteins and Monoclonal Antibodies, and Small Molecule Therapies, encompassing ATP-Competitive Inhibitors and Non-ATP-Competitive Inhibitors. When dissected by Disease Indication, it ranges from Autoimmune Disorders such as Crohn’s Disease and Rheumatoid Arthritis to Oncology, which covers Breast Cancer subtypes HER2-Positive and Hormone Receptor-Positive and Lung Cancer subtypes Non-Small Cell and Small Cell. Patient Demographics classification highlights Age Groups-Adult, Geriatric and Pediatric-and Gender categories Female, Male and Non-binary. Mechanism Of Action analysis distinguishes Inhibition Pathways, including Immune Checkpoint Inhibitors and Kinase Inhibitors, from Modulation Pathways such as Gene Modulation and Protein Modulation. Combination Strategies group Monotherapy Complementation like Anti-Inflammatories and Steroids, alongside Therapeutic Conjugates such as Antibody-Drug Conjugates and Peptide-Drug Conjugates. Lastly, End-user Applications split between Hospital Pharmacy and Specialty Clinics.

Regional Dynamics Influencing Market Adoption

Regional dynamics exhibit distinct patterns of adoption, infrastructure maturity and regulatory alignment. In the Americas, strong reimbursement frameworks and established biotech clusters accelerate clinical trial deployment and scale-up capabilities. Moreover, digital health integration enhances remote patient monitoring and real-world data collection. Meanwhile, Europe, Middle East & Africa displays a heterogeneous regulatory environment that challenges market entry but encourages innovation through public-private partnerships and adaptive pathways, particularly for rare autoimmune and oncology indications. In contrast, Asia-Pacific boasts rapid capacity expansion, driven by government incentives for domestic manufacturing and aggressive licensing agreements. Emerging markets in this region are leapfrogging traditional distribution models by leveraging telemedicine platforms and regional centers of excellence. These regional insights underscore the importance of tailored strategies that align with local policies, reimbursement schemes and patient access initiatives.

Competitive Landscape and Leading Companies

The competitive landscape is dominated by a mix of global pharmaceutical giants and specialized biotech innovators. AbbVie Inc., Amgen Inc. and AstraZeneca PLC drive momentum in immuno-oncology and fusion protein development, while Bayer AG and Boehringer Ingelheim International GmbH focus on kinase inhibitor portfolios. Bristol-Myers Squibb Company and Roche Holding AG continue to expand checkpoint inhibitor combinations, supported by strategic collaborations with Daiichi Sankyo Company, Limited and Pfizer Inc. Concurrently, Eli Lilly and Company and Gilead Sciences, Inc. accelerate small molecule R&D, whereas GlaxoSmithKline plc and Merck & Co., Inc. leverage their biologic pipelines for novel conjugates. Incyte Corporation and Syndax Pharmaceuticals, Inc. contribute niche expertise in modulation pathways, and Johnson & Johnson and Novartis AG exploit their global reach to optimize manufacturing footprints. Sanofi S.A. and Takeda Pharmaceutical Company Limited integrate monotherapy complementation strategies, while Regeneron Pharmaceuticals, Inc. and Pfizer Inc. pursue antibody-drug conjugates. This diversified cohort underscores the value of cross-sector alliances and targeted acquisitions to maintain leadership in a dynamic market.

Actionable Recommendations for Industry Leaders

To navigate this evolving environment, industry leaders should prioritize integrated R&D ecosystems that foster open innovation. Establishing co-development consortia with academic institutions and contract research organizations will accelerate candidate validation. Additionally, investing in advanced analytics platforms for real-world evidence and patient stratification will enhance clinical trial design and post-market surveillance.

Supply chain resilience demands a hybrid manufacturing model combining localized facilities with strategic suppliers. Organizations must proactively engage in scenario planning to address regulatory shifts, tariff fluctuations and raw material volatility. Moreover, adopting modular, continuous flow reactors can reduce batch cycle times and improve cost efficiencies.

Finally, forging value-based partnerships with payers and health systems will ensure reimbursement alignment and patient access. By offering outcome-linked contracts, companies can demonstrate therapeutic value and share financial risk, reinforcing long-term stakeholder engagement.

Conclusion: Navigating the Future of Dual Targeted Therapy

The dual targeted therapy market stands at an inflection point, where scientific innovation converges with evolving policy and economic realities. As transformative shifts reshape R&D and supply chain paradigms, success will hinge on agility, collaboration and data-driven decision-making. By leveraging nuanced segmentation insights, aligning regional strategies and cultivating strategic alliances, organizations can unlock sustainable growth and deliver unparalleled patient outcomes. The collective progress achieved thus far lays a robust foundation for future breakthroughs that will redefine standards of care across autoimmune disorders and oncology.

Market Segmentation & Coverage

This research report categorizes the Dual Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologic Drugs
    • Fusion Proteins
    • Monoclonal Antibodies
  • Small Molecule Therapies
    • ATP-Competitive Inhibitors
    • Non-ATP-Competitive Inhibitors
  • Autoimmune Disorders
    • Crohn's Disease
    • Rheumatoid Arthritis
  • Oncology
    • Breast Cancer
      • HER2-Positive Breast Cancer
      • Hormone Receptor-Positive Breast Cancer
    • Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
  • Age Groups
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
    • Non-binary
  • Inhibition Pathways
    • Immune Checkpoint Inhibitors
    • Kinase Inhibitors
  • Modulation Pathways
    • Gene Modulation
    • Protein Modulation
  • Monotherapy Complementation
    • Anti-Inflammatories
    • Steroids
  • Therapeutic Conjugates
    • Antibody-Drug Conjugates
    • Peptide-Drug Conjugates
  • Hospital Pharmacy
  • Specialty Clinics

This research report categorizes the Dual Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dual Targeted Therapy Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Syndax Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dual Targeted Therapy Market, by Type Of Therapy
8.1. Introduction
8.2. Biologic Drugs
8.2.1. Fusion Proteins
8.2.2. Monoclonal Antibodies
8.3. Small Molecule Therapies
8.3.1. ATP-Competitive Inhibitors
8.3.2. Non-ATP-Competitive Inhibitors
9. Dual Targeted Therapy Market, by Disease Indication
9.1. Introduction
9.2. Autoimmune Disorders
9.2.1. Crohn's Disease
9.2.2. Rheumatoid Arthritis
9.3. Oncology
9.3.1. Breast Cancer
9.3.1.1. HER2-Positive Breast Cancer
9.3.1.2. Hormone Receptor-Positive Breast Cancer
9.3.2. Lung Cancer
9.3.2.1. Non-Small Cell Lung Cancer
9.3.2.2. Small Cell Lung Cancer
10. Dual Targeted Therapy Market, by Patient Demographics
10.1. Introduction
10.2. Age Groups
10.2.1. Adult
10.2.2. Geriatric
10.2.3. Pediatric
10.3. Gender
10.3.1. Female
10.3.2. Male
10.3.3. Non-binary
11. Dual Targeted Therapy Market, by Mechanism Of Action
11.1. Introduction
11.2. Inhibition Pathways
11.2.1. Immune Checkpoint Inhibitors
11.2.2. Kinase Inhibitors
11.3. Modulation Pathways
11.3.1. Gene Modulation
11.3.2. Protein Modulation
12. Dual Targeted Therapy Market, by Combination Strategies
12.1. Introduction
12.2. Monotherapy Complementation
12.2.1. Anti-Inflammatories
12.2.2. Steroids
12.3. Therapeutic Conjugates
12.3.1. Antibody-Drug Conjugates
12.3.2. Peptide-Drug Conjugates
13. Dual Targeted Therapy Market, by End-user Applications
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Specialty Clinics
14. Americas Dual Targeted Therapy Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Dual Targeted Therapy Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Dual Targeted Therapy Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Amgen Inc.
17.3.3. AstraZeneca PLC
17.3.4. Bayer AG
17.3.5. Boehringer Ingelheim International GmbH
17.3.6. Bristol-Myers Squibb Company
17.3.7. Daiichi Sankyo Company, Limited
17.3.8. Eli Lilly and Company
17.3.9. Gilead Sciences, Inc.
17.3.10. GlaxoSmithKline plc
17.3.11. Incyte Corporation
17.3.12. Johnson & Johnson
17.3.13. Merck & Co., Inc.
17.3.14. Novartis AG
17.3.15. Pfizer Inc.
17.3.16. Regeneron Pharmaceuticals, Inc.
17.3.17. Roche Holding AG
17.3.18. Sanofi S.A.
17.3.19. Syndax Pharmaceuticals, Inc.
17.3.20. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DUAL TARGETED THERAPY MARKET MULTI-CURRENCY
FIGURE 2. DUAL TARGETED THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. DUAL TARGETED THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DUAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DUAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DUAL TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ATP-COMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY NON-ATP-COMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HORMONE RECEPTOR-POSITIVE BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY NON-BINARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY GENE MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PROTEIN MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PEPTIDE-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 117. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 118. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 119. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 121. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 122. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 123. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 124. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 125. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 127. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 128. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 130. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 131. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 132. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 133. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 134. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 143. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 146. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 150. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 151. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 152. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 209. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 210. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 211. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 212. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 213. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 215. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 216. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 217. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 218. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 219. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 220. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 222. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 223. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 224. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 225. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 226. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 227. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 228. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 229. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 230. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 231. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 232. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 233. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 234. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 235. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 237. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 238. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 240. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 241. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 242. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 243. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 244. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 263. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 264. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 265. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 266. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 267. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 268. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 269. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 270. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 271. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 272. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 273. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 274. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 275. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 277. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 278. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 279. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 280. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY INHIBITION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY MODULATION PATHWAYS, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION STRATEGIES, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY MONOTHERAPY COMPLEMENTATION, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC CONJUGATES, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY END-USER APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 320. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 322. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 323. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 324. SINGAPORE DUAL TARGETED THERAPY MARKET

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Syndax Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bispecific Antibodies Market - Global Forecast to 2030 - Product Image

Bispecific Antibodies Market - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Bispecific Antibodies - Global Strategic Business Report - Product Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • 104 Pages
  • Global
From
Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030 - Product Image

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders - Product Image

Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

  • Book
  • Global
Cancer Biological Therapy - Global Strategic Business Report - Product Image

Cancer Biological Therapy - Global Strategic Business Report

  • Report
  • 211 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.